Az influenza elleni védooltás hatékonysága immunszupprimált gyulladásos bélbetegekben.

Klaudia Farkas, Gabriella Terhes, Judit Deák, Anita Bálint, F. Nagy, Zoltán Szepes, T. Wittmann, T. Molnár

Research output: Article

2 Citations (Scopus)

Abstract

Inactivated influenza vaccination is recommended yearly for patients with inflammatory bowel disease on immunosuppressive therapy. The aim of our study was to evaluate the immune response to seasonal influenza vaccination in patients with inflammatory bowel disease treated with immunosuppressants. Thirty patients were enrolled in this prospective study. Each patient was diagnosed with inflammatory bowel disease and treated with immunosuppressants. Blood samples were obtained from patients before and one month after influenza vaccination (A/California/7/2009(H1N1), A/Perth/16/2009(H3N2) B/Brisbane/60/2008) to assess the pre-and postimmunization antibody titers. Virus-specific antibodies were measured by ELISA. The vaccine acceptance rate was 53.3%. Local adverse effect occurred in 5 patients. Seven patients developed systemic adverse events. Influenza-like symptoms occurred in 2 patients, although their antibody titers failed to increase significantly. Antibodies to influenza viruses were detected in each patient before the vaccination. The results confirmed that each patient had appropriate antibody titer as correlation of protection even before the immunisation. Seroprotection rates were not influenced by the vaccination. The vaccine seemed to be safe.

Original languageHungarian
Pages (from-to)1870-1874
Number of pages5
JournalOrvosi Hetilap
Volume153
Issue number47
Publication statusPublished - nov. 25 2012

Fingerprint

Influenza Vaccines
Immunosuppressive Agents
Inflammatory Bowel Diseases
Vaccination
Human Influenza
Antibodies
Therapeutics
Vaccines
Orthomyxoviridae
Immunization
Enzyme-Linked Immunosorbent Assay
Prospective Studies
Viruses

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Farkas, K., Terhes, G., Deák, J., Bálint, A., Nagy, F., Szepes, Z., ... Molnár, T. (2012). Az influenza elleni védooltás hatékonysága immunszupprimált gyulladásos bélbetegekben. Orvosi Hetilap, 153(47), 1870-1874.

Az influenza elleni védooltás hatékonysága immunszupprimált gyulladásos bélbetegekben. / Farkas, Klaudia; Terhes, Gabriella; Deák, Judit; Bálint, Anita; Nagy, F.; Szepes, Zoltán; Wittmann, T.; Molnár, T.

In: Orvosi Hetilap, Vol. 153, No. 47, 25.11.2012, p. 1870-1874.

Research output: Article

Farkas, K, Terhes, G, Deák, J, Bálint, A, Nagy, F, Szepes, Z, Wittmann, T & Molnár, T 2012, 'Az influenza elleni védooltás hatékonysága immunszupprimált gyulladásos bélbetegekben.', Orvosi Hetilap, vol. 153, no. 47, pp. 1870-1874.
Farkas K, Terhes G, Deák J, Bálint A, Nagy F, Szepes Z et al. Az influenza elleni védooltás hatékonysága immunszupprimált gyulladásos bélbetegekben. Orvosi Hetilap. 2012 nov. 25;153(47):1870-1874.
Farkas, Klaudia ; Terhes, Gabriella ; Deák, Judit ; Bálint, Anita ; Nagy, F. ; Szepes, Zoltán ; Wittmann, T. ; Molnár, T. / Az influenza elleni védooltás hatékonysága immunszupprimált gyulladásos bélbetegekben. In: Orvosi Hetilap. 2012 ; Vol. 153, No. 47. pp. 1870-1874.
@article{70d1abca08454cc89b0ee054472a9546,
title = "Az influenza elleni v{\'e}doolt{\'a}s hat{\'e}konys{\'a}ga immunszupprim{\'a}lt gyullad{\'a}sos b{\'e}lbetegekben.",
abstract = "Inactivated influenza vaccination is recommended yearly for patients with inflammatory bowel disease on immunosuppressive therapy. The aim of our study was to evaluate the immune response to seasonal influenza vaccination in patients with inflammatory bowel disease treated with immunosuppressants. Thirty patients were enrolled in this prospective study. Each patient was diagnosed with inflammatory bowel disease and treated with immunosuppressants. Blood samples were obtained from patients before and one month after influenza vaccination (A/California/7/2009(H1N1), A/Perth/16/2009(H3N2) B/Brisbane/60/2008) to assess the pre-and postimmunization antibody titers. Virus-specific antibodies were measured by ELISA. The vaccine acceptance rate was 53.3{\%}. Local adverse effect occurred in 5 patients. Seven patients developed systemic adverse events. Influenza-like symptoms occurred in 2 patients, although their antibody titers failed to increase significantly. Antibodies to influenza viruses were detected in each patient before the vaccination. The results confirmed that each patient had appropriate antibody titer as correlation of protection even before the immunisation. Seroprotection rates were not influenced by the vaccination. The vaccine seemed to be safe.",
author = "Klaudia Farkas and Gabriella Terhes and Judit De{\'a}k and Anita B{\'a}lint and F. Nagy and Zolt{\'a}n Szepes and T. Wittmann and T. Moln{\'a}r",
year = "2012",
month = "11",
day = "25",
language = "Hungarian",
volume = "153",
pages = "1870--1874",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "47",

}

TY - JOUR

T1 - Az influenza elleni védooltás hatékonysága immunszupprimált gyulladásos bélbetegekben.

AU - Farkas, Klaudia

AU - Terhes, Gabriella

AU - Deák, Judit

AU - Bálint, Anita

AU - Nagy, F.

AU - Szepes, Zoltán

AU - Wittmann, T.

AU - Molnár, T.

PY - 2012/11/25

Y1 - 2012/11/25

N2 - Inactivated influenza vaccination is recommended yearly for patients with inflammatory bowel disease on immunosuppressive therapy. The aim of our study was to evaluate the immune response to seasonal influenza vaccination in patients with inflammatory bowel disease treated with immunosuppressants. Thirty patients were enrolled in this prospective study. Each patient was diagnosed with inflammatory bowel disease and treated with immunosuppressants. Blood samples were obtained from patients before and one month after influenza vaccination (A/California/7/2009(H1N1), A/Perth/16/2009(H3N2) B/Brisbane/60/2008) to assess the pre-and postimmunization antibody titers. Virus-specific antibodies were measured by ELISA. The vaccine acceptance rate was 53.3%. Local adverse effect occurred in 5 patients. Seven patients developed systemic adverse events. Influenza-like symptoms occurred in 2 patients, although their antibody titers failed to increase significantly. Antibodies to influenza viruses were detected in each patient before the vaccination. The results confirmed that each patient had appropriate antibody titer as correlation of protection even before the immunisation. Seroprotection rates were not influenced by the vaccination. The vaccine seemed to be safe.

AB - Inactivated influenza vaccination is recommended yearly for patients with inflammatory bowel disease on immunosuppressive therapy. The aim of our study was to evaluate the immune response to seasonal influenza vaccination in patients with inflammatory bowel disease treated with immunosuppressants. Thirty patients were enrolled in this prospective study. Each patient was diagnosed with inflammatory bowel disease and treated with immunosuppressants. Blood samples were obtained from patients before and one month after influenza vaccination (A/California/7/2009(H1N1), A/Perth/16/2009(H3N2) B/Brisbane/60/2008) to assess the pre-and postimmunization antibody titers. Virus-specific antibodies were measured by ELISA. The vaccine acceptance rate was 53.3%. Local adverse effect occurred in 5 patients. Seven patients developed systemic adverse events. Influenza-like symptoms occurred in 2 patients, although their antibody titers failed to increase significantly. Antibodies to influenza viruses were detected in each patient before the vaccination. The results confirmed that each patient had appropriate antibody titer as correlation of protection even before the immunisation. Seroprotection rates were not influenced by the vaccination. The vaccine seemed to be safe.

UR - http://www.scopus.com/inward/record.url?scp=84873199536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873199536&partnerID=8YFLogxK

M3 - Article

C2 - 23160078

AN - SCOPUS:84873199536

VL - 153

SP - 1870

EP - 1874

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 47

ER -